EARLY DETECTORS OF DISEASE

CNA Diagnostics Inc.

CNAD

FORWARD-LOOKING INFORMATION

This presentation contains "forward-looking information", which is disclosureregarding possible events, conditions or financial performance that is based onassumptions about future economic conditions and courses of action. In particular,the forward-looking information in this presentation includes: statements regardingtiming and outcomes of research, development, and commercialization activities,financing activities, protection of intellectual property, market share and growth.Actual results may vary from the forward- looking information in this presentation.Material risk factors that could cause actual results to differ materially from theforward-looking information include: (i) CNAD’s ability to develop commerciallyviable products; (ii) CNAD’s ability to achieve profitability; (iii) CNAD’s ability toproduce and market its products; (iv) CNAD’s ability to obtain regulatory approvalof its products; (v) CNAD’s ability to protect its intellectual property; (vi) competitiveand alternative technologies; and (vii) CNAD’s ability to obtain financing to supportits operations. The material factors or assumptions that were used to develop theforward-looking information in this presentation include: our ability to achieveresearch and development objectives, timing of proposed commercialization plans,ability to protect intellectual property, ability to secure needed financing or ourability to develop sufficient margins in the business through development ofproposed technology or other means. CNAD's views regarding possible events,conditions or financial performance may change. However, CNAD does not intendto update the forward-looking information in this presentation, except as requiredby applicable securities legislation.

ABOUT CNAD

A new molecular diagnostics company

developing DNA biomarker collections

that enable "early accurate” diagnosis of

preclinical disease conditions.

Our “dedicated bioinformatics” discovery

pipeline and next generation sequencing

will change the way we confront and

diagnose disease.

Our goal is the well being of animals that

is inherently linked to the status of

human health.

GROWING PROBLEMS

The way we deal with animal health is now

becoming a serious problem to human health.

The use of clinical observation for diagnosis of

disease reduces treatment options.

Most human diseases (60%) and infections

(75%) originate from the livestock sector.

Researchers have found that 13 of 56 livestock

diseases and infections account for more than

2.2 million human deaths each year.

GROWING PROBLEMS

Antimicrobial resistance is branded by the CDC

as one of our most serious health threats, with

estimated costs of $100 trillion by 2050.

Each year 2 million people in the USA become

infected with bacteria that are resistant to

antibiotics increasing the infection rate at a faster

pace than can be controlled.

80% of the antibiotics sold in the USA are used

on livestock while China’s livestock industry will

consume 1/3 of the world’s available antibiotics.

OUR SOLUTIONS

Early and accurate diagnosis of chronic

disease and infections in animals and

humans needs to be implemented to

protect global communities and the

human food supply from diseases that are

detected too late by present diagnostic

methods.

The earlier the diagnosis of disease, the

more likely it can be cured or successfully

managed and treated, increasing food

production from healthy animals.

OUR SOLUTIONS

Early diagnosis of disease allows for managed

reduction in the use of antibiotics, stopping the

need for broad spectrum applications to food

producing animals not requiring treatment.

Provide the ability to create better vaccines and

drugs by determining their therapeutic effect on

disease and infections over specific time points

through the progress of the disease.

VALUE PROPOSITION Our diagnostic biomarker platform could

prevent substantial losses to livestock

producers, beginning with the U.S. Beef

and Dairy Industry, currently losing $10

billion per year.

Our Value:

Early pre-clinical diagnosis (BSE 10 mos.)

Accurate detection (Yes or No)

Low costs per test

Rapid results

High volume throughput

Onsite capable testing

Multiple disease analysis

GLOBAL IVD MARKET

2013 2014 2015 2016 2017 2018 2019 2020

Gro

wth

in B

illio

ns

Year

This market includes Immunoassay, Clinical

Chemistry, Molecular Diagnostics, and Hematology

The in vitro (IVD) diagnostics market is poised to

reach $75 Billion in annual revenue by 2020.

$75 bn

DNA DIAGNOSTIC MARKET

2013 2014 2015 2016 2017 2018 2019 2020

Gro

wth

in B

illio

ns

Year

As part of the Molecular Diagnostics Market,

DNA testing has extraordinary potential.

The DNA diagnostics market is expected to

reach $19 Billion by 2020.

$19 bn

Disease

Selection

& Samples

Sequencing &

Bioinformatics

Biomarker

Development

Clinical

Validation

OUR BUSINESS MODEL

Distributors

Biomarker Development & Commercialization

Royalty Licenses

Regulatory

Approvals

Regulatory

Approvals

Vete

rin

ary

Med

ical

Revenue

OUR MARKET POTENTIAL

TOTALS (millions) 244.6 243.9 81.8 (Beef) 97.6 (Dairy)

BEEF & DAIRY ONLY

FINANCIAL PROJECTIONS

Description

(000’s)

2017 2018 2019 2020

Revenues 4,213 40,704 80,241 120,913

Cost of Sales 1,453 10,259 17,654 23,040

Gross Profit 2,760 30,445 62,587 97,873

EBITDA (*2 Biomarkers - NA only)

- 163 25,305 57,594 92,521

One Test for BEEF & One Test for DAIRY

CANADA & USA

MILESTONES

Commercial Sales

Begin Two New Biomarkers for Beef & Dairy

Sign Exclusive Veterinary Distributors

Sub-License Medical Biomarkers

Completion of High Throughput Diagnostic Device

2017

2018

Two Biomarker Developments for Beef & Dairy

Validate Low Throughput Test Device and Begin High Throughput Diagnostic Device

Companion Animal, Breast Cancer & Sepsis Collaborations

Seeking $5 million Potential Grant Approvals

2016

IP Transfer from U of C

Acquire Disease Samples

Receive Order for 3 Million Tests

Grant Approval $382,705

2015

Begin Collaboration Partnerships

Appoint Industry Directors

Target Disease Samples

Grant Approval €658,000

2014

COMPETITORS

ANIMAL HUMAN

IDEXX ROCHE

ABAXIS QIAGEN

BIORAD

ZOETIS

THERMO FISHER

* Denotes (DNA preclinical based testing)

bioMERIEUX

ABBOTT

GRAIL BIO *

1 SOLUTIONS FOR INDUSTRY PROBLEMS

SCALABLE GLOBAL PRODUCTS

HIGH BARRIERS TO ENTRY

TRACTION WITH NEAR TERM REVENUE

CORPORATE HIGHLIGHTS

2

3

4

5 DRIVERS FROM INDUSTRY LEADERSHIP

CONTACT INFORMATION

CNA Diagnostics Inc.

610 – 1414 8th St. SW,

Calgary, AB T2R 1J6

Contact:

Greg McCartney - CEO

greg.m@cnadiagnostics.com

(604) 560-1239

Tim Uniacke - EVP

tim@cnadiagnostics.com

(403) 714-0888